Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Assessment of NAFLD Burden in an Employee Wellness Program Among Non-obese Patients Without Evident Metabolic Abnormalities

Endocrine Society's Annual Meeting

ENDO 2023

Chicago, IL, June 15-18, 2023

Poster presentation: Assessment of NAFLD Burden in an Employee Wellness Program Among Non-Obese Patients Without Evident Metabolic Abnormalities

Authors: Bril F, Louie J, Shiffman D, McPhaul MJ

Specialty: Cardiovascular disease, Cardiology, Endocrinology

Related content

Conference Presentation
Predicting Nonalcoholic Fatty Liver Disease in Adolescent Girls With Polycystic Ovary Syndrome and Obesity
Publication
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
Conference Presentation
Differences in HDL Particle Composition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Liver Fibrosis May Explain Higher Cardiovascular Risk

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.